mFOLFOX6: Clinical Trials

42 trials of mFOLFOX6, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 7 unknown, 6 not yet recruiting, 6 recruiting. 42 Phase 2, 8 Phase 1, 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 242Completed 13, Unknown 7, Not yet recruiting 6, Recruiting 6, Active not recruiting 5, Withdrawn 3, Terminated 2
Phase 18Completed 4, Active not recruiting 2, Recruiting 2
Phase 36Unknown 3, Completed 2, Not yet recruiting 1

Follow mFOLFOX6: new trials by email Literature Review of mFOLFOX6 trials Research Report on mFOLFOX6

Trials (filtered) newest first · largest first

All 42 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers
Zolbetuximab, mFOLFOX6, CAPOX - Advanced Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma
Phase 2Not yet recruitingMidhun Malla322026-11-012026-11-02
mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer
cmFOLFOXIRI plus PD-1 inhibitor, mFOLFOX6 - Colon Cancer (Stage II &Amp;Amp; III)
Phase 2Not yet recruitingSun Yat-sen University1382026-10-012026-05-22
NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC
Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer
Phase 2Not yet recruitingSixth Affiliated Hospital, Sun Yat-sen University1002026-09-012026-08-14
Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Cancer
mFOLFOX6, Suvemcitug, Enlonstobart - Rectal Cancer
Phase 2Not yet recruitingFudan University522026-08-282026-09-09
Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study)
mFOLFOX6, Serplulimab - Rectal Cancer
Phase 2Not yet recruitingXinhua Hospital, Shanghai Jiao Tong University School of Medicine1282026-02-012026-02-03
Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER
Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2, Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2, Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2 - Stage I Colon Cancer, Stage II Colon Cancer
Phase 2RecruitingBaylor College of Medicine282025-06-152025-05-25
A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)
Cetuxima-β, Envafolimab, mFOLFOX6 - Metastatic Colorectal Cancer (CRC)
Phase 2 / Phase 3Not yet recruitingSun Yat-sen University5902025-06-012025-05-06
SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer
Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer
Phase 2CompletedSixth Affiliated Hospital, Sun Yat-sen University492025-04-022026-08-04
Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients
mFOLFIRINOX, mFolfox6 - Rectum Cancer
Phase 2RecruitingMenoufia University1002025-01-252025-02-19
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
cadonilimab, Trastuzumab, XELOX - Metastatic HER2 Positive Gastroesophageal Junction Cancer
Phase 1 / Phase 2RecruitingZhejiang Cancer Hospital902024-07-102024-10-21
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine - Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma
Phase 1 / Phase 2RecruitingBoehringer Ingelheim9102024-06-282026-11-16
Total Neoadjuvant Therapy in Rectal Cancer
Short-course radiotherapy, mFOLFOX6 - Rectal Cancer
Phase 2RecruitingNational Cheng-Kung University Hospital422023-11-162026-04-08
Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer
mFOLFOXIRI + Cadonilimab, mFOLFOX6, mFOLFOXIRI - Colorectal Cancer
Phase 2RecruitingSun Yat-sen University1432023-07-102025-07-23
Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer
Cadonilimab Injection, Short-course radiotherapy, Consolidation chemotherapy - Locally Advanced Rectal Carcinoma
Phase 2CompletedShenzhen People's Hospital272023-04-112025-02-05
The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer
Fruquintinib, FOLFIRI, mFOLFOX6 - Metastatic Colorectal Cancer
Phase 2UnknownFudan University682022-12-012022-12-02
Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC
HLX07, HLX10, mFOLFOX6 - CRC
Phase 2UnknownShanghai Henlius Biotech502022-07-152022-05-03
Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC
Cetuximab, mFOLFOX6, FOLFIRI - Colorectal Cancer
Phase 2 / Phase 3UnknownRuijin Hospital2002021-11-012021-04-30
Neoadjuvant Therapy for Localized Rectal Adenocarcinoma
Chemoradiation, short course radiation therapy, mFOLFOX6 - Rectal Adenocarcinoma
Phase 2WithdrawnUNC Lineberger Comprehensive Cancer Center2021-08-132021-11-10
A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer
Durvalumab, FOLFOX, Short Course Radiotherapy (Arm A) - Rectal Cancer, Rectal Adenocarcinoma
Phase 2UnknownLiz-Anne Lewsley482020-12-072020-11-09
Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer
short-course radiotherapy, mFOLFOX6, Chemoradiotherapy - Rectal Cancer
Phase 2Active not recruitingKyungpook National University Hospital3642020-10-232026-02-12

Showing 20 of 42. Sign in to see all of them.

Conditions studied

Colorectal Neoplasms (15)  ·  Rectal Neoplasms (14)  ·  Colonic Neoplasms (5)  ·  Neoplasm Metastasis (3)  ·  Stomach Neoplasms (3)  ·  Pancreatic Neoplasms (2)  ·  Adenocarcinoma (1)  ·  Adenocarcinoma Of Esophagus (1)  ·  Breast Neoplasms (1)  ·  Carcinoma, Hepatocellular (1)  ·  Cold Hypersensitivity (1)  ·  Esophageal Neoplasms (1)  ·  Fowlpox (1)  ·  Neuralgia (1)  ·  Neuropathy, Painful (1)

Sponsors

Sun Yat-sen University (4)  ·  Amgen (2)  ·  Fudan University (2)  ·  Ruijin Hospital (2)  ·  Sixth Affiliated Hospital, Sun Yat-sen University (2)  ·  ASLAN Pharmaceuticals (1)  ·  AVEO Pharmaceuticals, Inc. (1)  ·  Aadi Bioscience, Inc. (1)  ·  Baruch Brenner (1)  ·  Baylor College of Medicine (1)  ·  Boehringer Ingelheim (1)  ·  Five Prime Therapeutics, Inc. (1)  ·  Gustave Roussy, Cancer Campus, Grand Paris (1)  ·  Hoosier Cancer Research Network (1)  ·  Kyungpook National University Hospital (1)

Countries

United States (18)  ·  China (13)  ·  Belgium (5)  ·  Italy (5)  ·  South Korea (5)  ·  Spain (5)  ·  United Kingdom (5)  ·  France (4)  ·  Germany (4)  ·  Australia (3)  ·  Canada (3)  ·  Hungary (3)  ·  Japan (3)  ·  Taiwan (3)  ·  Thailand (2)

Top investigators

Atif Iqbal, MD (1)  ·  Baruch Brenner, Prof (1)  ·  Charlie Qi, MD (1)  ·  Guohui Wan, PhD. (1)  ·  Jieer Ying, MD (1)  ·  Juan Huang, PhD. (1)  ·  Jun Huang, PhD. (1)  ·  Jun Zhang, MD & Ph.D (1)  ·  Michael S Lee, MD (1)  ·  Midhun Malla, MD, MS (1)  ·  Norman Wolmark, MD (1)  ·  Patrick Boland, M.D. (1)  ·  Peng Junjie (1)

Results publications

PMID 24457377, PMID 26032776, PMID 26049686, PMID 26109878, PMID 30081865, PMID 32965540, PMID 33207247, PMID 34446053, PMID 36244398, PMID 36852723, PMID 37923987, PMID 38084840, PMID 38308771, PMID 38309722, PMID 41108088, PMID 42134324

NIH funding

2014 (1), 2016 (1), 2017 (1), 2019 (1)